▁be ▁equivalent ▁in ▁effect iveness ▁to ▁ 2 5 0   m g / day ▁or al ▁cy pro ter one ▁ac et ate ▁as ▁a ▁mon other apy ▁in ▁the ▁treatment ▁of ▁pro state ▁cancer ▁in ▁a ▁large - scale ▁clin ical ▁trial ▁of ▁ 3 1 0   pat ients , ▁though ▁its ▁side ▁effect ▁and ▁to x icity ▁profiles ▁( including ▁gy ne com ast ia , ▁di arr he a , ▁n ause a , ▁loss ▁of ▁app et ite , ▁and ▁li ver ▁dist urban ces ) ▁were ▁regarded ▁as ▁consider ably ▁worse ▁than ▁those ▁of ▁cy pro ter one ▁ac et ate . ▁ ▁A ▁dos age ▁of ▁ 7 5 0   m g / day ▁fl ut am ide ▁( 2 5 0   m g / three ▁times ▁a ▁day ) ▁is ▁roughly ▁equivalent ▁in ▁terms ▁of ▁effect iveness ▁to ▁ 5 0   m g / day ▁b ical ut am ide ▁when ▁used ▁as ▁the ▁anti andro gen ▁component ▁in ▁combined ▁and ro gen ▁block ade ▁in ▁the ▁treatment ▁of ▁advanced ▁pro state ▁cancer . ▁ ▁Fl ut am ide ▁has ▁been ▁used ▁to ▁prevent ▁the ▁effects ▁of ▁the ▁test oster one ▁f lare ▁at ▁the ▁start ▁of ▁G n R H ▁ag on ist ▁ther apy ▁in ▁men ▁with ▁pro state ▁cancer . ▁ ▁The ▁combination ▁of ▁fl ut am ide ▁with ▁an ▁est ro gen ▁such ▁as ▁eth in yl est rad i ol ▁sul fon ate ▁has ▁been ▁used